Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Dezima Pharma

EU flag

Sandoz files for approval of Neulasta biosimilar in Europe

Amgen facing increasing competition in global biosimilar market

National Institute for Health and Care Excellence NICE logo

NICE backs Repatha but rejects cholesterol rival Praluent

New draft guidance marks a U-turn on Amgen's drug but knocks back Sanofi treatment

- PMLiVE

Mylan buys into six biosimilars, including Orencia candidate

Deal with Momenta bolsters biosimilars pipeline for new products

- PMLiVE

Amgen buys back product rights from GSK

Prolia, Xgeva and Vectibix brought back in-house

- PMLiVE

Amgen’s Kyprolis approved in Europe

Multiple myeloma drugwins licence three years after gaining US approval

- PMLiVE

Repatha’s price tag too rich for UK’s NICE

HTAbody turns the cholesterol-lowering antibody down in draft guidance

- PMLiVE

Amgen’s biosimilar shows clinical equivalence with Humira

ABP 501 as effective as AbbVie's blockbuster in phase III rheumatoid arthritis trial

- PMLiVE

Amgen gets FDA nod for virus-based melanoma therapy

Advisory committee votes in favour of drug after three month delay

- PMLiVE

Amgen’s Imlygic recommended for European approval

First-in-class oncolytic immunotherapy wins CHMP positive opinion

EU flag

CHMP October meeting gives recommendations for Pfizer and MSD

But the regulatory advisors sound note ofcaution on Biogen’s Tecfidera

- PMLiVE

Express Scripts ‘will pay $750m on PCSK9 inhibitors next year’

Amgen's Repatha and Sanofi's Praluent included

- PMLiVE

Clock ticking on biosimilar Enbrel in US

10-month review for drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links